公开(公告)号：US20180371099A1

公开(公告)日：2018-12-27

申请号：US16115343

申请日：2018-08-28

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Richard BOURGON ,  David FABRIZIO ,  Gregg FINE ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Sanjeev MARIATHASAN ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY

IPC: C07K16/28 ,  A61K39/395 ,  G16H50/30 ,  G16H20/10

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US20240190967A1

公开(公告)日：2024-06-13

申请号：US18237114

申请日：2023-08-23

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  A61K39/00 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: C07K16/2827 ,  C12Q1/6886 ,  G01N33/57407 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US20200031936A1

公开(公告)日：2020-01-30

申请号：US16655495

申请日：2019-10-17

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US20220153861A1

公开(公告)日：2022-05-19

申请号：US17590918

申请日：2022-02-02

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Richard BOURGON ,  David FABRIZIO ,  Gregg FINE ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Sanjeev MARIATHASAN ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY

IPC: C07K16/28 ,  A61K39/395 ,  G16H50/30

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US20180037655A1

公开(公告)日：2018-02-08

申请号：US15790680

申请日：2017-10-23

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  C12Q1/68 ,  G01N33/574

CPC classification number: C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57407 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.